HealthEquity (NASDAQ:HQY) Bolsa

HEALTHEQUITY INC

HealthEquity

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Oil,Field,Site,,In,The,Evening,,Oil,Pumps,Are,Running

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ATER

OABI

ONVO

Las acciones en EE. UU. suben a mitad de jornada, lideradas por un crecimiento en energía. El Dow sube 200 pts y el petróleo repunta.

Wall Street en alza: Dow sube 200 puntos mientras el petróleo y el oro se mantienen firmes

Pre-Market Outlook

FIVE

STNE

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: SIG, WSM, HQY, STNE y FIVE.

5 acciones en el foco este miércoles: SIG, WSM, HQY, STNE y FIVE

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

GETY

SGMO

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: IHS, HQY, GETY, SGMO y STNE.

5 acciones en el foco este martes: IHS, HQY, GETY, SGMO y STNE

HealthEquity Inc

In the last three months, 4 analysts have published ratings on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for HealthEquity, revealing an average target of $117.25, a high estimate of $125.00, and a low estimate of $112.00. Witnessing a positive shift, the current average has risen by 6.83% from the previous average price target of $109.75.
<img src="https://www.benzinga.com/files/images/story/2025/1742414451_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of HealthEquity among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to HealthEquity. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of HealthEquity's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into HealthEquity's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HealthEquity analyst ratings.</a>
<h2>Get to Know HealthEquity Better</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>Understanding the Numbers: HealthEquity's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining HealthEquity's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.55% as of 31 October, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): HealthEquity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.27%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): HealthEquity's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: HealthEquity's debt-to-equity ratio is below the industry average at 0.53, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

4 Analysts Assess HealthEquity: What You Need To Know

On Tuesday, HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported fourth-quarter adjusted EPS of 69 cents, up from 63 cents a year ago, <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44386926/healthequity-stock-falls-after-reporting-q4-results-revenue-beat-eps-miss-soft-guidance" rel="noreferrer noopener">missing the consensus of 72 cents.</a>
Revenue increased 19% year over year to $311.8 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44384524/healthequity-reports-fiscal-year-and-fourth-quarter-ended-january-31-2025-financial-results" rel="noreferrer noopener">consensus of $306.05 million</a>.
The health savings account custodian reported adjusted EBITDA of $107.8 million, an increase of 9%.
Health savings accounts (HSAs) as of January&nbsp;31, 2025, were 9.9&nbsp;million, an increase of 14% year over year, including 753,000 HSAs with investments, an increase of 23% year over year. As of January&nbsp;31, 2025, total accounts were 17.0 million, including 7.1 million other consumer-directed benefits (CDBs).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a>
Guidance: HealthEquity expects fiscal year 2026 revenue of $1.28 billion to $1.305 billion, compared to estimates of $1.301 billion.
The company anticipates adjusted EPS of $3.57 to $3.74, compared to the consensus of $3.71. Management expects Adjusted EBITDA of $525 million to $545 million.
Barrington Research maintains HealthEquity with an <a target="_blank" href="https://www.benzinga.com/quote/HQY/analyst-ratings" rel="noreferrer noopener">Outperform and a $112 price target.</a>
Analyst Alexander Paris writes the earnings were impacted by excess costs associated with cyber-fraud prevention and reimbursements.
&#8220;While the magnitude of the excess costs associated with cybersecurity fraud and prevention was more than expected, we are &#8220;looking over the valley&#8221; to better margins and earnings growth in 2H/26 and beyond,&#8221; analyst Paris writes.
With HQY&#8217;s strong HSA business and higher cash yields expected in the coming years, the analyst writes that the company&#8217;s overall financial and operational performance will keep improving once temporary extra costs subside.
Price Action: HQY stock is down 18.9% at $82.46 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44394046/oracle-integrates-nvidia-ai-enterprise-and-secures-major-defense-cloud-deal-with-singapore" target="_blank" rel="noreferrer noopener">Oracle Integrates NVIDIA AI Enterprise and Secures Major Defense Cloud Deal with Singapore</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Guidance

Health Care

Price Target

Reiteration

Movers

General

HealthEquity's Long-Term Growth Intact Despite Short-Term Margin Pressures, Analyst Says

<h3>Gainers</h3>
<ul>
<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) stock moved upwards by 29.1% to $2.17 during Wednesday's regular session. The company's market cap stands at $122.9 million. </li>
<li>Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) shares moved upwards by 23.13% to $0.6. The company's market cap stands at $175.8 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares moved upwards by 22.58% to $2.47. The market value of their outstanding shares is at $1.6 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 17.85% to $3.3. The company's market cap stands at $139.5 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock moved upwards by 17.37% to $3.35. The company's market cap stands at $2.2 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock rose 16.98% to $1.86. The market value of their outstanding shares is at $16.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 19.9% to $16.45 during Wednesday's regular session. The company's market cap stands at $91.9 million. The company's, Q4 earnings came out yesterday. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock decreased by 17.91% to $1.88. The market value of their outstanding shares is at $28.5 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) stock declined by 17.54% to $83.84. The market value of their outstanding shares is at $7.2 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) stock decreased by 16.84% to $1.68. The company's market cap stands at $8.3 million. </li>
<li>OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) shares decreased by 15.84% to $2.69. The market value of their outstanding shares is at $324.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock fell 14.49% to $17.95. The company's market cap stands at $46.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

BDTX

CANF

HURA

INTS

LYEL

SCNX

TNXP

VERO

VTVT

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 200 points on Wednesday.
The Dow traded up 0.55% to 41,808.59 while the NASDAQ climbed 0.95% to 17,671.26. The S&amp;P 500 also rose, gaining, 0.66% to 5,651.61.
Check This Out: <a href="https://www.benzinga.com/25/03/44396179/how-to-earn-500-a-month-from-jabil-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Jabil Stock Ahead Of Q2 Earnings</a>
Leading and Lagging Sectors Energy shares rose by 1.2% on Wednesday.
In trading on Wednesday, real estate shares fell by 0.7%.
Top Headline
The EIA said crude oil inventories in the US increased by 1.745 million barrels in the week ended March 14, compared to market estimates of a 1.1 million gain.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Service Properties Trust &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVC#NASDAQ">SVC</a>) shares shot up 18% to $2.94 after Wells Fargo upgraded the stock from Underweight to Overweight and raised its price target from $2.5 to $4.</li>
<li>Shares of Aterian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>)got a boost, surging 31% to $2.7640 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>BGM Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGM#NASDAQ">BGM</a>) shares were also up, gaining 16% to $11.79 after the company announced the acquisition of YX for $95 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares dropped 18% to $83.35 after the company reported worse-than-expected fourth-quarter adjusted EPS results.</li>
<li>Shares of Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) were down 30% to $0.2815 after the company announced a 1-for-12 reverse stock split.</li>
<li>OmniAb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) was down, falling 17% to $2.6545 following fourth-quarter earnings.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $67.38 while gold traded down 0.1% at $3,040.50.
Silver traded down 1.6% to $34.275 on Wednesday, while copper rose 1.2% to $5.0765.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.12%, Germany's DAX 40 fell 0.55% and France's CAC 40 gained 0.65%. Spain's IBEX 35 Index rose 0.30%, while London's FTSE 100 rose 0.08%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei falling 0.25%, China's Shanghai Composite Index falling 0.1%, Hong Kong's Hang Seng Index gaining 0.12% and India's BSE Sensex gaining 0.20%.
Economics
<ul>
<li>U.S. mortgage applications declined by 6.2% in the second week of March, following a cumulative 37% increase from the two prior weeks.</li>
<li>The EIA said crude oil inventories in the US increased by 1.745 million barrels in the week ended March 14, compared to market estimates of a 1.1 million gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks">Jim Cramer Says TJX Is &#8216;Terrific,&#8217; Recommends Buying These Stocks</a></li>
</ul>

Dow Surges Over 200 Points; US Crude Oil Inventories Increase More than Expected

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and maintains $112 price target.

Barrington Research Maintains Outperform on HealthEquity, Maintains $112 Price Target

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Shares of Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/ABSI/earnings">worse-than-expected fourth-quarter financial results.</a>
Absci reported quarterly losses of 25 cents per share which missed the analyst consensus estimate of 23 cents per share. This is unchanged from the same period last year. The company reported quarterly sales of $665.000 thousand which missed the analyst consensus estimate of $1.778 million.
Absci shares dipped 9.4% to $2.79 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares dipped 16.1% to $26.50 in pre-market trading after climbing 70% on Tuesday.</li>
<li>Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>) shares fell 14.8% to $6.43 in pre-market trading.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares declined 14.7% to $86.68 in pre-market trading after the company reported worse-than-expected quarterly earnings results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 13% to $17.87 in pre-market trading following weak quarterly sales.</li>
<li>Waterdrop Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) declined 6.5% to $1.30 in pre-market trading following a 5% fall on Tuesday.</li>
<li>Resolute Holdings Management, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RHLD#NASDAQ">RHLD</a>) declined 4.3% to $34.53 in pre-market trading after dipping 18% on Tuesday.</li>
<li>Target Hospitality Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) fell 3.8% to $5.63 in pre-market trading.</li>
<li>Alpha Technology Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) fell 3.2% to $31.47 in pre-market trading after gaining 14% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

ABSI

ATGL

RHLD

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock moved upwards by 45.4% to $2.93 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.9 million. </li>
<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) stock moved upwards by 32.73% to $2.23. The company's market cap stands at $126.3 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares moved upwards by 22.55% to $2.88. The market value of their outstanding shares is at $113.4 million. </li>
<li>Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) stock rose 18.68% to $4.51. The market value of their outstanding shares is at $207.6 million. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) stock moved upwards by 17.58% to $1.07. The market value of their outstanding shares is at $16.4 million. </li>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock increased by 12.41% to $0.65. The company's market cap stands at $18.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares decreased by 19.9% to $0.36 during Wednesday's pre-market session. The company's market cap stands at $22.2 million. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) stock decreased by 18.52% to $2.86. The market value of their outstanding shares is at $386.7 million. </li>
<li>Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) shares decreased by 16.13% to $15.76. The market value of their outstanding shares is at $2.6 billion. </li>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares declined by 15.61% to $85.8. The company's market cap stands at $7.4 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock fell 14.88% to $26.9. The company's market cap stands at $350.0 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) shares fell 12.85% to $1.56. The market value of their outstanding shares is at $30.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

CRGX

IMVT

INNV

NXTC

OSRH

PASG

TELA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

HealthEquity shares are trading lower after the company reported worse-than-expected Q4 Adj. EPS results.

U.S. stock futures advanced on Wednesday ahead of the Federal Open Market Committee&#8217;s (FOMC) decision on the interest rates. Futures of all four benchmark indices were higher in premarket trading.
On Tuesday, the stocks plunged after a two-day rally as the Magnificent 7 stocks dragged the indices down. Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) GTC AI Conference failed to ignite a rally despite a slew of announcements.
The two-day FOMC meeting began on Tuesday, and the Federal Reserve Chairman Jerome Powell is expected to announce its decision during a press conference on Wednesday afternoon.
The 10-year Treasury yield stood at 4.29%, while the two-year yield was at 4.05%. According <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> the CME Group's FedWatch tool, there is a 99% chance that the Federal Reserve will keep interest rates unchanged.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.16%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.26%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.02%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.28%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Wednesday. The SPY was up 0.26% to $562.46, and the QQQ advanced 0.35% to $476.22, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Technology, communication services, and consumer discretionary sectors led U.S. stock declines on Tuesday, with the Nasdaq Composite falling roughly 300 points.
Specifically, Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) dropped about 4%, and Nvidia Corp. fell over 3%.
The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) also saw a decline exceeding 1%. In contrast, energy and healthcare stocks rose, defying the broader market&#8217;s downward trend.
Economic data showed that U.S. import prices increased by 0.4% in February, exceeding expectations, while export prices rose 0.1%. The U.S. industrial production also surpassed estimates, increasing by 0.7% in February.
The Nasdaq 100 index continues to be in the correction zone as it was still 12.33% lower from its previous high. While Dow Jones was 7.75% lower, S&amp;P 500 declined 8.67% from their respective 52-week highs.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.71%</td>
<td>17,504.12 </td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.07%</td>
<td>5,614.66</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.62%</td>
<td>41,581.31</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.89%</td>
<td>2,049.94</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
"No rate change is expected," noted senior economist at WisdomTree, Jeremy Siegel ahead of the Federal Reserve&#8217;s decision, adding that the dot plot will be updated. The market is pricing in two rate cuts this year, he says, but he's "not convinced that the Fed will fully signal that just yet."
Furthermore, Siegel anticipates Powell will face intense scrutiny regarding declining market sentiment and inflation concerns.
He believes market direction hinges on the tariff situation; further escalation by President Donald Trump could trigger a significant downturn, potentially a &#8220;bear market&#8221;. Regarding Big Tech, Siegel argues current valuations, excluding Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), are high but not bubble-like, unlike the 2000 tech boom.
&#8220;For now, tariffs remain the dominant market force. The path forward depends on how Trump navigates trade policy—any softening would be bullish for equities, while continued escalation would put further downside pressure on stocks,&#8221; Siegel added.
&#8220;We don't expect any surprises at this week&#8217;s FOMC meeting, with the Fed likely holding the federal funds rate in the 4.25% to 4.5% range,&#8221; said Collin Martin, director, of fixed income strategy at the Schwab Center for Financial Research
&#8220;With growth concerns now making the most headlines, Fed Chairman Powell will likely be asked about the balance of risks given that all of the uncertainty out there could weigh on the labor market. We still expect rate cuts later this year, likely in the second half,&#8221; said Martin
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Wednesday:
<ul>
<li>FOMC will announce its decision on interest rates at 2:00 p.m., and Federal Reserve Chairman Jerome Powell will address a press conference at 2:30 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Signet Jewelers Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) was up 0.31% in premarket on Wednesday ahead of its earnings before the opening bell. Analysts expect earnings of $6.25 per share on revenue of $2.33 billion.</li>
</ul>
<ul>
<li>Williams-Sonoma Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) advanced 1.17% as Wall Street expects it to report earnings of $2.93 per share on revenue of $2.35 billion before the opening bell.</li>
</ul>
<ul>
<li>Five Below Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) rose 1.26% ahead of its earnings after the closing bell. Analysts expect earnings of $3.38 per share on revenue of $1.39 billion.</li>
</ul>
<ul>
<li>Healthequity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) slumped 13.09% after it posted downbeat earnings for its fourth quarter on Tuesday.</li>
</ul>
<ul>
<li>StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) jumped 8.02% after reporting better-than-expected fourth-quarter earnings and sales results.</li>
</ul>
<ul>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) was 2.01% higher after it announced an AI server lineup with new Nvidia GPU support.</li>
</ul>
<ul>
<li>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained 1.06% ahead of the second day of the GTC AI conference.</li>
</ul>
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) climbed 2.96% after receiving approval for rolling out its first Robotaxi in California.</li>
</ul>
<ul>
<li>TEN Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) surged 33.63% after it announced that it would initiate a $1 million stock repurchase program on March 17, 2025, with no set end date, funded by operating cash and subject to market conditions.</li>
</ul>
<ul>
<li>5E Advanced Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEAM#NASDAQ">FEAM</a>) plunged 20.72% after it announced a resale of up to 20.63 million common shares by stockholders; the company will receive no proceeds and will cover all the expenses.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.63% to hover around $66.33 per barrel.
The gold spot index was down by 0.12% to $3,030.36 per ounce. Its last record high was at $3,045.39 per ounce. The Dollar Index was up by 0.35% at the 103.608 level.
Asian markets closed mixed on Wednesday with China&#8217;s CSI 300, South Korea's Kospi, Hong Kong's Hang Seng, and India's S&amp;P BSE Sensex advancing in trade. Japan's Nikkei 225, and Australia's ASX 200 index declined. European markets were also mixed in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44392370/nvidia-destroys-420-billion-of-investor-wealth-since-deepseek-launch-valuation-hits-a-29-month-low-as-gtc-fails-to-ignite-stock">Nvidia Loses $420 Billion In Market Capitalization Since DeepSeek Launch, Valuation Hits A 29-Month Low As GTC Fails To Ignite Stock</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Market Summary

Futures

Federal Reserve

FEAM

NVDA

PLTR

SMCI

TSLA

XHLD

US Stocks Likely To Open Higher Ahead Of FOMC Decision: 'Tariffs Remain The Dominant Market Force' Amid Rising Economic Uncertainty, Says Expert

Shares of StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/STNE/earnings">earnings and sales results</a>.
StoneCo shares jumped 8% to $10.64 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Leishen Energy Holding Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSE#NASDAQ">LSE</a>) gained 90% to $14.31 in pre-market trading after jumping over 46% on Tuesday. The company recently reported FY24 financial results.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) rose 35.4% to $0.1760 in pre-market trading after the company announced positive results from a beagle dog dose range-finding study.</li>
<li>TEN Holdings, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) gained 34% to $0.7839 in pre-market trading. TEN Holdings shares jumped 18% on Tuesday after the company announced a $1 million stock repurchase program.</li>
<li>Aterian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) gained 27% to $2.68 in pre-market after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Bowen Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOWN#NASDAQ">BOWN</a>) gained 24% to $5.43 in pre-market trading after jumping 5% on Tuesday.</li>
<li>CARGO Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) gained 21.1% to $4.60 in pre-market trading after the company suspended CRG-023 &amp; allogeneic platform and initiated 90% workforce reduction.</li>
<li>Hillenbrand, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>) gained 17.3% to $29.29 in pre-market trading.</li>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) rose 11.8% to $1.32 in pre-market trading after dipping 23% on Tuesday.</li>
<li>CNS Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) rose 10.4% to $3.92 after surging 16% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>FST Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBSX#NASDAQ">KBSX</a>) fell 23.1% to $4.22 in pre-market trading after gaining 310% on Tuesday.</li>
<li>5E Advanced Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEAM#NASDAQ">FEAM</a>) shares fell 21.2% to $3.08 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) fell 18.5% to $0.2012 in pre-market trading after gaining around 22% on Tuesday. Starbox Group company received staff determination notice from Nasdaq.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) declined 16.1% to $26.50 in pre-market trading after climbing 70% on Tuesday.</li>
<li>OSR Holdings, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) dipped 15.5% to $1.51 in pre-market trading after jumping 34% on Tuesday.</li>
<li>Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>) shares tumbled 14.8% to $6.43 in pre-market trading.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares fell 14.7% to $86.68 in pre-market trading after the company reported worse-than-expected quarterly earnings results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares dipped 13% to $17.87 in pre-market trading following weak quarterly sales.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) fell 9.4% to $2.79 in today's pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Waterdrop Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) fell 6.5% to $1.30 in pre-market trading after declining around 5% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

BOWN

CNSP

INTZ

KBSX

STBX

VRPX

Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Signet Jewelers Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) to report quarterly earnings at $6.25 per share on revenue of $2.33 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Signet shares gained 0.3% to $48.42 in after-hours trading.</li>
<li>Analysts are expecting Williams-Sonoma Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) to post quarterly earnings at $2.93 per share on revenue of $2.35 billion. The company will release earnings before the markets open. Williams-Sonoma shares fell 1.6% to close at $172.28 on Tuesday.</li>
<li>HealthEquity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) posted downbeat earnings for its fourth quarter on Tuesday. HealthEquity expects fiscal year 2026 revenue of $1.28 billion to $1.305 billion versus estimates of $1.301 billion. The company anticipates full-year earnings of $3.57 to $3.74 per share versus estimates of $3.71 per share. HealthEquity shares dipped 13.7% to $87.75 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) reported better-than-expected fourth-quarter earnings and sales results. StoneCo shares jumped 10.2% to $10.85 in the after-hours trading session.</li>
<li>Analysts expect Five Below Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) to post quarterly earnings at $3.38 per share on revenue of $1.39 billion after the closing bell. Five Below shares rose 1.3% to $74.88 in after-hours trading.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>
Photo courtesy: Shutterstock

Williams-Sonoma, HealthEquity And 3 Stocks To Watch Heading Into Wednesday

HealthEquity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported fourth-quarter financial results after the market close on Tuesday and shares are sinking. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/03/g44384524/healthequity-reports-fiscal-year-and-fourth-quarter-ended-january-31-2025-financial-results">of the report</a>.
<ul>
<li>Q4 Revenue: $311.82 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $306.05 million</li>
</ul>
<ul>
<li>Q4 Adjusted EPS: 69 cents, versus estimates of 72 cents</li>
</ul>
Total revenue was up 19% on a year-over-year basis. The company reported 9.9 million health savings accounts (HSAs) as of Jan. 31, up 14% year-over-year. Total accounts came in at 17 million as of Jan. 31. Total HSA assets were up 27% year-over-year to $32.1 billion.
HealthEquity said it repurchased 1.4 million shares of its common stock in fiscal 2025 for $122.2 million. The company had $177.8 million remaining under its buyback as of Jan. 31.
&#8220;Team Purple finished fiscal ‘25 in strong fashion, with record revenues and major strides in advancing our strategic initiatives, allowing us to provide our&nbsp;outlook&nbsp;for an even stronger fiscal ‘26,&#8221; said Scott Cutler, president and CEO of HealthEquity. 
&#8220;With a focus on Member First Secure Mobile Experiences, we are executing against our 3Ds strategy to Deepen partnerships, Deliver remarkable experiences, and Drive member outcomes for our Clients, Network Partners, and members.&#8221;
Outlook: HealthEquity expects fiscal year 2026 revenue of $1.28 billion to $1.305 billion versus estimates of $1.301 billion. The company anticipates full-year earnings of $3.57 to $3.74 per share versus estimates of $3.71 per share.
The guidance came in below estimates at the midpoint, which appears to be weighing on shares after hours.
HealthEquity executives will further discuss the quarter on a call with investors and analysts at 4:30 p.m. ET.
HQY Price Action: <a href="http://benzinga.com/quote/hqy">HealthEquity shares</a> were down 12.46% after hours, trading at $89 at the time of publication Tuesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44385576/five-below-q4-earnings-preview-analyst-less-optimistic-due-to-macro-tariffs-and-short-holiday-season">Five Below Q4 Earnings Preview: Analyst Less Optimistic Due To Macro, Tariffs And Short Holiday Season</a></li>
</ul>
Photo: Shutterstock.

Insurance

HealthEquity Stock Falls After Reporting Q4 Results: Revenue Beat, EPS Miss, Soft Guidance

<h3>Gainers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares moved upwards by 28.9% to $0.17 during Tuesday's after-market session. The company's market cap stands at $3.0 million. </li>
<li>Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) shares increased by 19.99% to $4.56. The market value of their outstanding shares is at $209.9 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares rose 14.88% to $1.09. The company's market cap stands at $16.7 million. </li>
<li>Pulmatrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PULM#NASDAQ">PULM</a>) shares moved upwards by 12.02% to $8.29. The company's market cap stands at $30.2 million. </li>
<li>OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) shares increased by 8.46% to $3.46. The market value of their outstanding shares is at $418.7 million. As per the news, the Q4 earnings report came out today. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock increased by 6.91% to $1.7. The company's market cap stands at $14.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) stock fell 12.3% to $89.15 during Tuesday's after-market session. The market value of their outstanding shares is at $7.7 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 10.57% to $28.26. The company's market cap stands at $367.7 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) stock declined by 9.6% to $0.7. The market value of their outstanding shares is at $29.0 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock declined by 7.26% to $11.5. The company's market cap stands at $34.9 million. </li>
<li>Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) stock declined by 7.1% to $2.88. The company's market cap stands at $330.7 million. As per the press release, Q4 earnings came out today. </li>
<li>Savara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRA#NASDAQ">SVRA</a>) stock decreased by 6.63% to $2.62. The market value of their outstanding shares is at $449.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PULM

RLYB

SVRA

XCUR

12 Health Care Stocks Moving In Tuesday's After-Market Session

Earnings Beats

CORRECTION: HealthEquity Q4 2025 Adj. EPS $0.69 Misses $0.72 Estimate, Sales $311.817M Beats $306.053M Estimate

HealthEquity Sees FY26 $3.57-$3.74 Vs $3.71 Est.; Revenue $1.280B-$1.305B Vs $1.301B Est.

U.S. stock futures were flat on Tuesday after a bounce back on Monday. Futures of all four benchmark indices were mixed in premarket trading.
On Monday, stocks continued their recovery from last week&#8217;s sell-off, which had pushed the S&amp;P 500 into correction territory amid growing concerns over the U.S. economy&#8217;s ability to withstand President Donald Trump&#8216;s trade war.
The two-day meeting of the Federal Open Market Committee will begin today as they discuss and announce their decision on interest rates slated to be released tomorrow. Chairman Jerome Powell will address a press conference on Wednesday afternoon.
The 10-year Treasury yield stood at 4.31%, while the two-year yield was at 4.04%. According <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> the CME Group's FedWatch tool, there is a 99% chance that the Federal Reserve will keep interest rates unchanged tomorrow.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.21%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.02%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.22%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped slightly in premarket on Monday. The SPY was down 0.15% to $566.37, and the QQQ also declined 0.25% to $481.54, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Real estate, energy, and consumer staples stocks led Monday&#8217;s market rally, with significant gains across the S&amp;P 500. Conversely, consumer discretionary stocks dipped.
This sector-driven strength propelled the Dow Jones higher extending the market&#8217;s recovery after last week&#8217;s sharp declines, which saw the Dow lose 3.1% and the S&amp;P 500 drop over 2%.
In company news, Guess? Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) shares surged 30% on acquisition interest, and Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) shares climbed 9% following the launch of new AI models.
Economic data presented a mixed picture, with retail sales growth below expectations, a sharp drop in the NY Empire State Manufacturing Index, and a decline in housing market confidence.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.31%</td>
<td>17,808.66</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.64%</td>
<td>5,675.12</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.85%</td>
<td>41,841.63</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.19%</td>
<td>2,068.33</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
The market sentiment seemed to be recovering on Monday after the S&amp;P 500 index recorded an upmove in 90% of its issues for two consecutive days. Ryan Detrick of Carson Research highlighted that this was a rare occurrence when 90% of S&amp;P 500 constituents rose back-to-back for two days.
According to the historical data shared by him, this has only happened 12 times since 1972 and the index has been higher in all instances after a year.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Back-to-back 90% advancing issues for the S&amp;P 500. Using <a href="https://twitter.com/NDR_Research?ref_src=twsrc%5Etfw">@NDR_Research</a> data back to 1972 shows higher six and 12 months later every single time, with much better than average returns. I&#39;m sure this will make everyone mad, but it made me &#x1f603; <a href="https://t.co/QWf8lJx2eQ">pic.twitter.com/QWf8lJx2eQ</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1901824344839336317?ref_src=twsrc%5Etfw">March 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Liz Ann Sonders and Kevin Gordon of Charles Schwab said in a note "The only thing we can be certain of is that things will remain uncertain for the time being."
They quoted the data from a few years ago when confidence metrics went through a soft patch giving a &#8220;false&#8221; recessionary signal amid strong underlying growth and the hard data. They termed it as a &#8220;vibecession.&#8221;
Whereas they termed the current period as &#8220;vibespansion," which was evident a few months ago, however, many strong sentiment metrics are receding. "If the soft data stay soft long enough, we see more risk of the hard data catching down," the note added.
Edward Yardeni or Yardeni Research highlighted that the markets could have bottomed out on Thursday last week and rose on Friday and Monday because there was no comment from Trump on tariffs.
He said, "From a sentiment perspective, it is possible that Thursday's selloff followed by Friday's rally marked a bottom in the correction. We will be more inclined to call a bottom when we see the stock market move higher on a day or days when Trump blusters about tariffs again, which he did not do on Friday."
"Any day without a Trump tariff comment is a good day for the market. We know that on April 2 there will be lots of reciprocal tariffs imposed on many more nations by the administration, undoubtedly eliciting lots of comments from Tariff Man," he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul>
<li>February&#8217;s housing starts, building permits, and import price index data will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Also, February&#8217;s industrial production and capacity utilization data will be released at 9:15 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>IHS Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) was up 0.77% in premarket on Tuesday ahead of its earnings before the opening bell. Analysts expect earnings of 4 cents per share on revenue of $424.00 million.</li>
</ul>
<ul>
<li>HealthEquity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) advanced 0.28% as Wall Street expects it to report earnings of 72 cents per share on revenue of $306.05 million after the closing bell.</li>
</ul>
<ul>
<li>StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STN#NASDAQ">STN</a>) rose 0.49% ahead of its earnings after the closing bell. Analysts expect earnings of 35 cents per share on revenue of $647.56 million.</li>
</ul>
<ul>
<li>Getty Images Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) jumped 2.33% after posting an upbeat earnings result for its fourth quarter on Monday.</li>
</ul>
<ul>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) dropped 6.83% after reporting worse-than-expected fourth-quarter financial results.</li>
</ul>
<ul>
<li>Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) was 4.39% higher continuing the momentum from yesterday following the launch of new AI models.</li>
</ul>
<ul>
<li>Bon Natural Life Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) surged 29.71% after it secured $12 million in gross proceeds from a best efforts unit offering.</li>
</ul>
<ul>
<li>Harrow Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) zoomed 24.14% after it projected 2025 revenue of over $280 million, driven by branded products.</li>
</ul>
<ul>
<li>Bakkt Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) plunged 30.24% after it rescheduled its fourth-quarter earnings call to March 18, 2025.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.35% to hover around $68.28 per barrel.
The gold spot index was up by 0.70% to $3,022.11 per ounce. Its last record high was at $3,028.49 per ounce. The Dollar Index was down by 0.05% at the 103.322 level.
Asian markets closed higher on Tuesday with China&#8217;s CSI 300, Japan's Nikkei 225, South Korea's Kospi, Australia's ASX 200, Hong Kong's Hang Seng, and India's S&amp;P BSE Sensex advancing in trade. European markets were also higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44371661/ai-bubble-bursting-magnificent-7s-profit-margins-face-pressure-as-capital-spending-can-tumble-in">AI Bubble Bursting? Magnificent 7&#8217;s Profit Margins Face Pressure As &#8216;Capital Spending Can Tumble&#8217; In 2025</a></li>
</ul>
Photo courtesy: Shutterstock

Economics

BIDU

Bakkt Holdings, Inc. Class A Common Stock

BKKT

HROW

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'

<h3>Companies Reporting Before The Bell</h3>
• Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $131.50 million. 
• United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) is expected to report quarterly loss at $0.41 per share on revenue of $9.50 million. 
• Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $185.00 million. 
• Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $10.68 million. 
• MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) is expected to report earnings for its fourth quarter. 
• Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $211.54 million. 
• McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) is projected to report earnings for its fourth quarter. 
• ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) is estimated to report earnings for its fourth quarter. 
• HUYA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $215.25 million. 
• XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is projected to report earnings for its fourth quarter. 
• UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) is expected to report earnings for its fourth quarter. 
• KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $4.01 billion. 
• Tencent Music Enter Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $1.01 billion. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report earnings for its fourth quarter. 
• OneConnect Financial Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) is likely to report earnings for its fourth quarter. 
• IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $413.76 million. 
• Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) is projected to report earnings for its fourth quarter. 
• Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is estimated to report quarterly earnings at $1.95 per share on revenue of $1.78 billion. 
• SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) is expected to report earnings for its fourth quarter. 
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) is likely to report quarterly earnings at $0.46 per share on revenue of $1.66 billion. 
• Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $0.93 per share on revenue of $30 thousand. 
• Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) is projected to report earnings for its fourth quarter. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its fourth quarter. 
• Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is likely to report earnings for its fourth quarter. 
• Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is projected to report quarterly loss at $1.19 per share on revenue of $26.90 million. 
• Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is estimated to report quarterly loss at $0.63 per share on revenue of $23.69 million. 
• Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) is likely to report quarterly loss at $0.21 per share on revenue of $1.82 million. 
• OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) is likely to report quarterly loss at $0.10 per share on revenue of $10.13 million. 
• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is estimated to report quarterly earnings at $0.72 per share on revenue of $305.07 million. 
• StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $647.56 million. 
• Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) is likely to report quarterly loss at $0.25 per share on revenue of $272.22 million. 
• Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

BEKE

BETR

CTRN

ESLT

ETON

FLOC

HUYA

INKT

OCFT

ORLA

SNDL

SRFM

TIGR

TRVI

USEA

WALD

XPEV

Earnings Scheduled For March 18, 2025

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) will release its fourth-quarter financial results, after the closing bell, on <a href="https://www.benzinga.com/quote/hqy/earnings">Tuesday, March 18.</a>
Analysts expect the Draper, Utah-based company to report quarterly earnings at 72 cents per share, up from 63 cents per share in the year-ago period. HealthEquity projects quarterly revenue of $305.82 million, compared to $262.39 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 9, 2024, HealthEquity posted mixed results for the third quarter.
HealthEquity shares gained 3.4% to close at $100.72 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barrington Research analyst Alexander Paris maintained an Outperform rating and a price target of $112 on March 14, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Raymond James analyst C. Gregory Peters maintained an Outperform rating and raised the price target from $105 to $120 on Feb. 25, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Mizuho analyst Steven Valiquette initiated coverage on the stock with an Outperform rating and a price target of $126 on Dec. 4, 2024. This analyst has an accuracy rate of 60%.</li>
<li>B of A Securities analyst Allen Lutz maintained a Buy rating and raised the price target from $100 to $120 on Nov. 13, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Deutsche Bank analyst George Hill maintained a Buy rating and increased the price target from $102 to $103 on Sept. 4, 2024. This analyst has an accuracy rate of 61%.</li>
</ul>
Considering buying HQY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-1024x583.png" alt="" class="wp-image-828822" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>

Long Ideas

HealthEquity Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Extreme Fear&#8221; zone on Monday.
U.S. stocks settled higher on Monday, with the Dow Jones index surging more than 350 points during the session. All three of the major indices recorded back-to-back gains.
Despite gains recorded on Monday, US stocks recorded losses last week. The Dow dipped around 3.1% to record its worst week since March 2023. The S&amp;P 500 dipped more than 2%, recording its fourth straight losing week.
Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) shares jumped 30% on Monday after the company announced it received a non-binding proposal from WHP Global to acquire the company for $13 per share in cash. Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) shares gained 9% after the company announced the launch of ERNIE 4.5 and deep-thinking model ERNIE X1.
On the economic data front, U.S. retail sales rose 0.2% month-over-month in February following a revised 1.2% decline in January but down from market expectations of a 0.6% rise. The NY Empire State Manufacturing Index declined 26 points to -20.0 in March, recording the lowest reading since May 2023. The NAHB/Wells Fargo Housing Market Index fell to 39 in March versus a reading of 42 in February.
Most sectors on the S&amp;P 500 closed on a positive note, with real estate, energy, and consumer staples stocks recording the biggest gains on Monday. However, consumer discretionary stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 353 points to 41,841.63 on Monday. The S&amp;P 500 rose 0.64% to 5,675.12, while the Nasdaq Composite climbed 0.31% at 17,808.66 during Monday's session.
Investors are awaiting earnings results from IHS Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>), HealthEquity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) , and StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 22.1, the index remained in the &#8220;Extreme Fear&#8221; zone on Monday, versus a prior reading of 20.9.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:<a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo courtesy: Shutterstock

CWCO

SAIC

Dow Jumps 350 Points Following Positive Economic Data: Investor Fear Eases, But Greed Index Remains In 'Extreme Fear' Zone

Press Releases

HealthEquity Reports Third Quarter Ended October 31, 2024 Financial Results

HealthEquity Caps 2024 With Widespread Recognition For Its Workplace Excellence

HealthEquity Announces Record Year-End HSA Sales Outlook, Presentation at J.P. Morgan Healthcare Conference

Tech-Powered Innovation Transforms Member Experiences and Earns HealthEquity Industry Recognition

HealthEquity Reports Year-End Sales Metrics

The Path Forward: How Commuting Impacts the Return to Office Experience

Forbes and U.S. News & World Report Agree: HealthEquity is One of America's Best Places to Work

HealthEquity Community Foundation Announces First Grant Recipients and Opens Next Funding Cycle

HealthEquity Assist™: A new suite of integrated benefit solutions that drive deeper engagement, deliver cost savings, and increase transparency for employee benefits

HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2025 Financial Results

Comments

HealthEquity

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL